New data published by the UK Health Security Agency (UKHSA) has revealed that London is potentially at risk of a measles resurgence.
UKHSA modelling suggests that, unless MMR vaccination rates improve, London could see a measles outbreak with tens of thousands of cases.“Those who have never received a measles vaccine (MMR) are at risk,” said UKHSA.MMR is part of the NHS Routine Childhood Immunisation Programme. Parents whose infants missed out, or anyone of any age unvaccinated, are urged to come forward.Susceptibility is particularly high among 19 to 25 year olds, affected by unfounded stories in the early 2000s (‘Wakefield cohorts’) and some may still not be fully vaccinated.As part of continued efforts to protect people against getting measles, the NHS is launching a campaign encouraging people to check their vaccination status, with targeted outreach to groups in London.Data published today by the UK Health Security Agency (UKHSA) shows there has been a steady rise in measles cases this year. It shows, between 1 January and 30 June this year there have been 128 cases of measles, compared to 54 cases in the whole of 2022, with 66 per cent of the cases detected in London although cases have been seen in all regions.The UKHSA assessment finds the risk of a measles epidemic across the UK is considered low. However, with lower current levels of coverage in London, a measles outbreak of between 40,000 and 160,000 cases could occur in the capital.The assessment also concludes that there is a high risk of cases linked to overseas travel leading to outbreaks in specific population groups such as young people and under-vaccinated communities.The risk in London is primarily due to low vaccination rates over several years, further impacted by the COVID-19 pandemic, particularly in some areas and groups where coverage of the first MMR dose at 2 years of age is as low as 69.5%.NHS England has launched a targeted national campaign to encourage uptake of the MMR vaccine, including targeted outreach work in London for those identified as at high risk and communities with the lowest uptake of vaccination.This Site is Intended for Healthcare Professionals Only
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Start your day right!
Get the latest updates and insights delivered to your inbox
Related News
More For You
The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.
iStock
Chemotherapy-free leukaemia treatment shows promise during trial
Jun 17, 2025
In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.
The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.
Researchers from Leeds wanted to assess whether two targeted cancer drugs could perform better than chemotherapy among patients with CLL.
They conducted a Flair trial at 96 cancer centres across the UK involving 786 people.
People with previously untreated CLL were randomly assigned to receive standard chemotherapy; a single targeted drug, ibrutinib, or two targeted drugs taken together, ibrutinib and venetoclax.
Ibrutinib is a cancer growth blocker that stops signals the cancer cells use to divide and grow.
Venetoclax blocks the functions of a protein found in CLL cells.
Researchers found that after five years, 94 per cent of patients who received ibrutinib plus venetoclax were alive with no disease progression.
That compared with 79 per cent for those on ibrutinib alone and 58 per cent for those on chemotherapy.
The study has been published in the New England Journal of Medicine and presented to the European Haematology Association congress in Milan, Italy.
Meanwhile, 66 per cent of patients on the new combination had no detectable cancer in their bone marrow after two years, compared with none of the people who received ibrutinib alone and 48 per cent on chemotherapy.
Dr Talha Munir, consultant haematologist at Leeds Teaching Hospitals NHS Trust, who led the study, described the trial outcome as a "milestone".
Dr Iain Foulkes, executive director, Cancer Research UK, which funded the trial along with AbbVie, and Johnson and Johnson, expressed satisfaction with the outcome and observed it could lead to a more targeted treatment of CLL.
Keep ReadingShow less
Most Popular
Don’t Miss Out
Get the latest updates and insights delivered to your inbox.
By subscribing, you agree to our Terms & Conditions.
View Terms & Conditions×
Terms and Conditions
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Asian Trade
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at
data@amg.biz
to see how we manage and store your data.
Locum pharmacists in the UK work in a difficult environment, and many are dissatisfied with their jobs.
iStock
Locums should stand up for their interests, say 'no' to unfair terms: PDA
Jun 17, 2025
The Pharmacists' Defence Association (PDA) has advised locum pharmacists to be vigilant about their interests and negotiate directly with their businesses, avoid working with digital platforms driven by algorithms, and be aware of regressive contract terms.
The not-for-profit organisation issued such an advisory following its survey of 1,300 UK locum pharmacists, which showed that they work in a difficult environment and that most are dissatisfied with their jobs.
Their grievances include declining rates of pay with often non-existent opportunities for negotiation, non-payment of legitimately incurred expenses, and some contractors operating unscrupulously with last-minute changes to agreed shifts and questionable contract terms.
On the other hand, with the increasing focus on 'Pharmacy First', there is an increase in their scope of work and expectations.
But past surveys have shown that competent staff are in short supply.
The PDA survey found that locum pharmacists face more barriers than their employed peers in accessing professional development and training.
Some universities bar them from taking up Independent Prescribing courses.
Many locums expressed concern that their work is not valued, though the scope of their services has increased.
The PDA observed that adverse pharmacy eco-systems have resulted in locum pharmacists accepting poor treatment in a way that many trades, such as plasterers, plumbers, and electricians, would not tolerate.
However, it observed that it doesn’t have to be like that if locum reps follow best practices.
The PDA exhorted locums to consider the collective advice from its locum representatives before entering into a contract, and think about the wider consequences of accepting terms which they truly believe are not appropriate.
Every time a locum accepts a lower rate or unfair contractual clauses, this enables unscrupulous businesses to make that the norm.
The PDA advised locums to negotiate directly with the company or the business owner.
This will help them get better rates of pay and a clearer understanding of the expectations of them in the workplace, it added.
The PDA has a dim view of platform and algorithmic working, and wants locums to avoid them.
While the contribution of a pharmacist is very different from many other “gig economy” workers, the technology and thinking behind platforms built around algorithms aim to minimise the cost to the client business while ensuring a payment is still secured for the platform owners.
The absence of the ability to negotiate a rate might be considered one of several red flags, it added.
PDA wants locums to be fully aware of the terms under which they are proposed to be engaged, and be aware of regressive contract terms.
It advised locums to decline the work if some terms appear problematic and to seek alternative work elsewhere.
While taking up a contract, Locums should take into account whether their employers are ready to pay for their travel and accommodation expenses.
If an employer does not offer reasonable travel or accommodation remuneration, or an increased rate to reflect those extra costs conferred, then deduct it from the overall payment being offered and consider again if the hourly rate is reasonable.
Keep ReadingShow less
Wales ranked worst for second-trimester abortion access in the UK
Jun 16, 2025
A leading healthcare charity has revealed that Wales is the worst part of the United Kingdom for allowing surgical abortions for women.
Surgical abortion is the process removing pregnancy from the womb by inducing local anaesthesia, conscious sedation or general anaesthesia.
The British Pregnancy Advisory Service (BPAS) said Wales was ‘astonishingly’ behind Northern Ireland, where abortion was decriminalised only in 2019 as per the British Pregnancy Advisory Service (BPAS).
Each year about 175 women travel from Wales to England for care, said Rachael Clarke, BPAS member.
The charity added that some women from South Wales were left 'traumatised' for being sent away to conduct the procedure.
The government said they have accepted necessary improvements for mid-trimester (13 to 27 weeks) abortion services, and women should have the access to essential healthcare services near to home.
The funding and service delivery for mid-trimester abortion care is a long term goal for around six to ten years.
Abortion is legal up to 24 weeks of pregnancy with the approval of two doctors in Wales, England and Scotland.
Prior to the decriminalization of abortion in Northern Ireland, abortion was only allowed in specific situations.
Northern Ireland now allows second trimester abortions beyond 20 weeks, and Scotland allows abortions only upto 20 weeks.
However, Wales only has limited provision of abortion after 14 weeks due to skills gap and doctor shortages.
The first women’s health plan for Wales, published last year in December, listed abortion as a fundamental right of women. It declared that facilities must be local and timely available for women to minimize complication, distress and cost.
The Welsh government had been asked to act for the improvement women’s health since 2018, said MS Sioned Williams.
"We are working with NHS Wales to identify and address the specific barriers to providing surgical abortion services locally and we are exploring what short-term improvements we can make while developing a robust, sustainable service for the future", said a Welsh government spokesperson.
Keep ReadingShow less
Charity reopens funding to ease back to school financial pressures for community pharmacists
Jun 16, 2025
Community pharmacists struggling with the costs of their children going back to school can apply for funding from The Leverhulme Trade Charities Trust (LTCT)
The Trust is providing up to £100,000 of support to those working in a community pharmacy or are a registered pharmacist or pharmacy technician
The fund offers £150 per eligible child - for up to three children per household - helping to cover costs such as school uniforms, stationery and travel.
Eligible applicants must also be in receipt of Universal Credit or Child Tax Credit for school-age children (aged 4-18 as of 31st August 2025) and have household savings under £4,000.
The application process is simple, though families are encouraged to ensure they have the correct documentation ready to upload, as incomplete or incorrect information is the most common reason for applications being rejected.
The fund will remain open until 1st July or until the budget is fully allocated.
Professor Anna Vignoles CBE FBA, Director at The Leverhulme Trade Charities Trust, says: “Following the success of last year’s initiative, we’re pleased to bring back the School Essentials Grant for those working in community pharmacy.
“Helping families through life’s financial hurdles is at the heart of what we do. Education is a critical pathway to opportunity and social mobility, and we know that the costs of getting children ready for school each year can weigh heavily on family budgets.
“It is our hope that this extra support will once again give families the breathing space they need during what can be a financially demanding time.”
The Pharmacy School Essentials Grant is managed on behalf of the Leverhulme Trade Charities Trust by GroceryAid. Applications are strictly confidential and employers will not be informed of who has applied. GroceryAid will process all applications and data in line with GDPR.
To find out more about eligibility and apply for the Pharmacy School Essentials Grant, visit: www.leverhulme-trade.org.uk.
Keep ReadingShow less
Germany's BioNTech to buy CureVac to boost cancer research
Jun 16, 2025
Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.
BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".
Both biotech companies have been working for years in the area of mRNA vaccines and treatments, which provoke an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells.
While the technology became well known in relation to some Covid-19 vaccines, it is also being used in other areas, and scientists believe it could be a game-changer against many diseases.
BioNTech said the acquisition of CureVac would help boost its work in the field of mRNA-based cancer immunotherapy -- treatment that uses the body's own immune system to fight diseases.
"This transaction is another building block in BioNTech's oncology strategy and an investment in the future of cancer medicine," said BioNTech CEO Ugur Sahin.
It was aimed at "establishing new standards of care for various types of cancer in the coming years," he said.
Alexander Zehnder, CEO of CureVac, said the purchase would bring scientific expertise, technology and manufacturing know-how "in the mRNA field under one roof".
BioNTech's all-stock acquisition has been unanimously approved by the companies' management and supervisory boards, and is expected to close in 2025, subject to certain conditions including regulatory approvals.
Both companies are listed on the Nasdaq Composite Index.
They had both sought to develop Covid-19 vaccines during the pandemic, with Mainz-based BioNTech's Comirnaty jab winning approval and going on to become one of the most widely used shots against the virus around the world.
But Tuebingen-based CureVac, founded 25 years ago by mRNA pioneer Ingmar Hoerr, abandoned its efforts in late 2021 after disappointing trial results.
In 2022, CureVac sued BioNTech for patent infringement over its rival's use of the technology.
Keep ReadingShow less
Load More
© Copyright 2025 Garavi Gujarat Publications Ltd & Garavi Gujarat Publications USA Inc